

Medical benefit drug policies are a source for WyoBlue Advantage medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and therefore subject to change.

P&T Date: 04/10/2025

Spravato® (esketamine)

HCPCS: J3490, S0013

Policy:

Requests must be supported by submission of chart notes and patient specific documentation.

- A. Coverage of the requested drug is provided when all the following are met:
 - a. Diagnosis of depressive symptoms in adults with Major Depressive Disorder with acute suicidal ideation
 - i. Must receive standard of care treatment for acute suicidal ideation, including a comprehensive treatment plan that involves cognitive behavioral therapy or interpersonal psychotherapy and optimization or initiation of oral antidepressant therapy.
 - OR
 - b. Diagnosis of treatment resistant depression (TRD)
 - i. Trial and failure of at least two different oral antidepressants AND two augmentation therapies for at least 6 weeks. Each oral antidepressant and augmentation therapy must be used in combination with each other (augmentation therapies include but are not limited to lithium, buspirone, and olanzapine).
 - ii. Pharmacotherapy must be in combination with cognitive behavioral therapy or interpersonal psychotherapy weekly for at least 8 weeks of treatment to yield at least moderate improvement (20% diminution in symptoms). If no improvement, the clinician should review and reappraise the treatment plan.
 - c. Prescribed by or in consultation with a psychiatrist
 - d. Must not be used in combination with intravenous ketamine
 - e. FDA approved age
 - f. Trial and failure, contraindication, or intolerance to the preferred drugs as listed in WyoBlue Advantage's utilization management medical drug list.
- B. Quantity Limitations, Authorization Period and Renewal Criteria
 - a. Quantity Limits: Align with FDA recommended dosing.
 - b. Authorization Period:
 - i. Acute suicidal ideation: 60 days
 - ii. TRD: 60 days initially then 6 months at a time thereafter
 - c. Renewal Criteria:
 - i. Acute suicidal ideation: Not applicable as no further authorization will be provided
 - ii. TRD: Documented improvement in symptoms of depression

***Note: Coverage and approval duration may differ for Medicare Part B members based on any applicable criteria outlined in Local Coverage Determinations (LCD) or National Coverage Determinations (NCD) as determined by Center for Medicare and Medicaid Services (CMS). See the CMS website at <http://www.cms.hhs.gov/>. Determination of

coverage of Part B drugs is based on medically accepted indications which have supported citations included or approved for inclusion determined by CMS approved compendia.

Background Information:

- Spravato is a N-methyl-D-aspartate (NMDA) receptor antagonist indicated for the treatment of TRD in adults, as monotherapy or in conjunction with an oral antidepressant, and for depressive symptoms in patients with Major Depressive Disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.
- TRD is a subset of MDD that is unresponsive to traditional and/or first-line therapeutic options. Though there is not a universal definition or staging model for TRD, a commonality among the many that have been proposed is an inadequate response to at least two trials of antidepressant pharmacotherapy.
- Antidepressants and psychotherapy are recommended first-line options to treat depression by The American Psychiatry Association guidelines for the treatment of depression (2010) and The American Psychological Association clinical practice guideline for the treatment of depression (2019). If at least a moderate improvement in symptoms is not observed within 4–8 weeks of treatment initiation, the diagnosis should be reappraised, side effects assessed, complicating comorbid conditions and psychosocial factors reviewed, and the treatment plan adjusted.
- For most patients, a selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI) is an optimal treatment option, though other antidepressants like mirtazapine or bupropion can also be considered. Initial selection of an antidepressant medication is largely based on the anticipated side effects, safety or tolerability of side effects for the individual patient, pharmacological properties of the medication, and additional factors such as medication response in prior episodes, cost, and patient preference.
- Treatment plan adjustments can include optimizing current medication dose if the side effect burden is tolerable and the upper limit of a medication dose has not been reached. Additional opportunities include switching to another antidepressant from the same class or a different class or augmenting the antidepressant with psychotherapy or other pharmacologic agents.
- Pharmacologic augmentation of antidepressants can utilize other non-monoamine oxidase inhibitor (MAOI) antidepressants, generally from a different pharmacologic class, lithium, thyroid hormone, or a second-generation antipsychotic.
- Psychotherapy options with clinical evidence supporting their use include cognitive behavioral therapy (CBT), interpersonal psychotherapy, psychodynamic therapy, and problem-solving therapy. Effectiveness studies have demonstrated similar effects across psychotherapy. When combining treatment with psychotherapy and pharmacologic agents, the American Psychological Association recommends CBT or interpersonal psychotherapy with an SSRI or SNRI. Guidelines confirm a 20% higher response rate when combining pharmacotherapy and various forms of time-limited psychotherapies with the larger impact seen among patients with more severe symptoms and among those with more chronic depressive disorders.
- Spravato's approval for TRD in combination with an oral antidepressant was based on the Phase III SUSTAIN-1 and TRANSFORM-2 clinical trials that showed statistically significant superiority of Spravato over placebo in patients with TRD. TRANSFORM-2 measured the short-term (four week) efficacy of Spravato while SUSTAIN-1 evaluated long-term efficacy.
 - In TRANSFORM-2, patients were randomized to Spravato (flexible dose; 56 mg or 84 mg) or placebo nasal spray in combination with an oral antidepressant (either duloxetine, escitalopram, sertraline, or extended-release venlafaxine) in 3 phases: a screening/prospective observational phase (4-7 weeks), a double-blind induction phase (4 weeks), and a follow-up phase (24 weeks). The Spravato active group showed a greater

improvement from baseline to day 28 in mean Montgomery-Asberg Depression Rating Scale (MADRS) compared to the placebo group (primary endpoint $p=0.020$).

- In the longer-term SUSTAIN-1 trial, patients were randomized to a 5 phase study consisting of a screening/prospective observational phase (4-7 weeks) and open-label induction phase (4 weeks) for direct-entry patients only, an optimization phase (12 weeks; open-label for direct-entry patients and double-blind for transfer-entry patients), a maintenance phase (variable duration; double-blind for all patients), and a follow-up phase (2 weeks) with a primary efficacy endpoint of time to relapse among stable remitters during the maintenance phase. Spravato active group significantly delayed relapse compared to placebo ($p=0.003$) along with the risk of relapse decreased by 51%.
- The oral antidepressants used in these trials were provided by the sponsor and represented the most commonly used standard of care antidepressants. The choice of which to administer was determined by the investigator based on patient-centric factors and availability in the participating study country.
- Positive results from the Phase IV, double-blind, placebo-controlled TRD4005 study supported Spravato's label expansion for the treatment of TRD as monotherapy. As with the combination therapy trials, patients met DSM-5 criteria for MDD and in the current depressive episode, had not responded adequately to at least two different antidepressants of adequate dose and duration. Patients were randomized to twice-weekly doses of intranasal Spravato 56 mg, 84 mg, or placebo for four weeks. Spravato demonstrated rapid and superior improvement across all 10 MADRS items at day 28 compared to placebo, with statistically superior improvement demonstrated as early as day 2 with Spravato monotherapy. The effect was observed at day 2 and remained through day 28, at which point 7.6% of patients taking placebo and 22.5% of patients taking Spravato achieved total remission (MADRS total score ≤ 12). Additionally, the safety profile of Spravato as monotherapy was consistent with existing clinical and real-world data of Spravato when used in combination with oral antidepressants.
- For the treatment of suicidal behaviors in patients with MDD, American Psychiatric Association guidelines (2010) recommend selecting an antidepressant agent with a low risk of toxicity in overdose, such as an SSRI or SNRI. In highly anxious or agitated patients, trazadone, low dose second-generation antipsychotics, gabapentin, and divalproex may be used. Benzodiazepines should be used only in the short term if the benefits outweigh the risks. Patients with acute suicidal ideation should be treated in the setting that is least restrictive, yet most likely to be safe and effective. Guidelines have not been updated to include the place in therapy of any ketamine products.
- Two Phase III clinical trials, ASPIRE I and ASPIRE II, evaluated Spravato's use in patients with moderate to severe MDD and acute suicidal ideation. Patients were given Spravato 84 mg twice weekly for 4 weeks or placebo. All patients received comprehensive standard of care treatment, including an inpatient psychiatric hospitalization and a newly initiated or optimized oral antidepressant therapy. Antidepressant therapy consisted of either antidepressant monotherapy or an antidepressant plus augmentation therapy. Augmentation medications considered to be standard of care included typical and atypical antipsychotics, lithium, anticonvulsants, and any additional antidepressants used in conjunction with another antidepressant. Spravato plus the standard-of-care treatment reduced MADRS by 15.9 and 16.0 points, in ASPIRE I and II respectively, compared to placebo. The secondary endpoint of reduction in suicidal ideation severity was not met.
- The use of Spravato, in conjunction with an oral antidepressant, beyond 4 weeks has not been systematically evaluated in the treatment of depressive symptoms in patients with MDD with acute suicidal ideation or behavior. Additionally, the effectiveness of Spravato in preventing suicide has not been demonstrated. Use of Spravato does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of Spravato.

- Guidelines have not been updated to include the place in therapy of any ketamine products. There is no literature supporting the safety and efficacy of Spravato in combination with intravenous (IV) ketamine, which is often used off-label for psychiatric indications like TRD and MDD with suicidal ideation despite the lack of FDA approval.

References:

1. American Psychiatric Association. Arlington (VA): Practice Guidelines for the Treatment of Patients with Major Depressive Disorder. November 2010. Available from: http://www.psychiatryonline.com/pracGuide/PracticePDFs/PG_Depression3rdEd.pdf. Accessed on October 15, 2022.
2. American Psychiatric Association. Arlington (VA): Practice Guidelines for the Assessment and Treatment of Patients With Suicidal Behaviors. November 2010. Available from: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/suicide.pdf. Accessed on October 15, 2022.
3. American Psychological Association. (2019). Clinical practice guideline for the treatment of depression across three age cohorts. Retrieved from <https://www.apa.org/depression-guideline> on November 20, 2022.
4. Clinicaltrials.gov. A study of intranasal esketamine plus an oral antidepressant for relapse prevention in adult participants with treatment-resistant depression (SUSTAIN-1). (NCT02493868) Available at: <https://clinicaltrials.gov/ct2/show/NCT02493868>. Accessed on March 7, 2019.
5. Clinicaltrials.gov. A study to evaluate the efficacy, safety, and tolerability of intranasal esketamine plus an oral antidepressant in elderly participants with treatment-resistant depression (TRANSFORM-3). (NCT02422186) Available at: <https://clinicaltrials.gov/ct2/show/NCT02422186>. Accessed on March 7, 2019.
6. Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. *JAMA Psychiatry*. 2019;76(9):893-903.
7. Data on File. Janssen Medical Information and Services. October 2022.
8. Fu DJ, Ionescu DF, Li X, et al. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I). *J Clin Psychiatry*. 2020;81(3):19m13191.
9. Ionescu DF, Fu DJ, Qiu X, et al. Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II). *Int J Neuropsychopharmacol*. 2021;24(1):22-31.
10. IPD Analytics RxBrief: Spravato Nasal Spray Approved for Adults with Major Depressive Disorder with Acute Suicidal Ideation. September 2020.
11. Johnson and Johnson Press Release. Janssen announces U.S. FDA approval of spravato (esketamine) CIII nasal spray for adults with treatment-resistant depression (TRD) who have cycled through multiple treatments without relief. March 5, 2019. Available at: <https://www.janssen.com/janssen-announces-us-fda-approval-spravato-esketamine-ciii-nasal-spray-adults-treatment-resistant>. Accessed on March 7, 2019.
12. Manufacturer press release. Spravato (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression. January 21, 2025. Accessed on February 3, 2025. Available at: <https://www.prnewswire.com/news-releases/spravato-esketamine-approved-in-the-us-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression-302355833.html>
13. Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. *Am J Psychiatry*. 2019;176(6):428-438.
14. Spravato [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; January 2025.
15. Wisniewski SR, Fava M, Trivedi MH, et al. Acceptability of second-step treatments to depressed outpatients: a STAR*D report. *Am J Psychiatry* 2007; 164:753–760.

Policy History		
#	Date	Change Description
1.0	Initial Effective Date: 01/01/2026	New Policy

** The prescribing information for a drug is subject to change. To ensure you are reading the most current information it is advised that you reference the most updated prescribing information by visiting the drug or manufacturer website or <http://dailymed.nlm.nih.gov/dailymed/index.cfm>.*